



Saluggia, January 17th, 2011

START UP OF THE TREASURY SHARES BUY-BACK PLAN OF DIASORIN SPA

DiaSorin announces its willing to start up the treasury shares buy-back plan for the purpose of new Stock-Options Plan of the Company under the terms and provisions authorized by the Shareholders Meeting dated April 27th, 2010.

The purchase will be carried out up to a maximum of 750.000 DiaSorin common shares, equal to 1,35% of the Company's share Capital, within the final term of 18 months as of the aforementioned Shareholders' resolution.

The purchase will be executed at a unit price not lower by more than 15% or higher by more than 15% than the official price posted for the DiaSorin shares during the Stock Market trading section that preceded each buy transaction.

In the event of purchases, DiaSorin will communicate on a daily basis to the Market and to the competent Authorities the transactions details along with any other information required by the applicable Laws.

For any further detail please refer to the Information Memorandum ("Relazione Informativa") of the Board of Directors published by DiaSorin under applicable Law, also on the Company's internet website www.diasorin.com.

The Chief Executive Officer

About DiaSorin

DiaSorin S.p.A., an international player in the market for in vitro diagnostics, develops, produces and markets reagent kits for clinical laboratory diagnostics. The DiaSorin Group is comprised of 23 companies based in Europe, North, Central and South America, Africa and Asia. It has about 1,500 employees, including more than 110 research and development specialists, and operates six manufacturing and research facilities in Saluggia (Vercelli, Italy), Dietzenbach (Germany), Stillwater (USA), Dublin (Ireland), Dartford (UK) and Johannesburg (SA). The last two were part of the Murex business operations, recently acquired from the Abbott Group. Thanks to its direct sales organization and an international network of over 80 independent distributors, the Group is present in more than 60 countries, offering a broad array of high quality products that includes comprehensive lines for each of the clinical segments in which the Group operates: infectious and viral diseases, management of bone and calcium related diseases, thyroid pathologies, oncology and fertility testing.

For additional information, please visit our website: www.DiaSorin.it

Contacts:

Investor Relations Director

Laura Villa

DiaSorin S.p.A.

laura.villa@DiaSorin.it

+39 0161487532

+39 348 15 11 542

Press Office

Carolina Mailander

c.mailander@mailander.it

+39 335 655 56 51

Bruno Caprioli

caprioli@mailander.it

+39 335 590 14 02